Tag: Excel Diagnostics & Nuclear Oncology Center
Excel Diagnostics and Nuclear Oncology Center Selected For New Investigational PRRT Treatment and Gallium Scan for Carcinoid and Neuroendocrine Tumor Patients
May 15, 2013
For carcinoid, pancreatic neuroendocrine tumor, and other NET cancer patients seeking the most advanced nuclear medicine opportunities in the United States, Excel Diagnostics and Nuclear Oncology Center in Houston, Texas, in collaboration with…
READ MOREFirst U.S. Center to Enroll Patients in International, Multicenter Clinical Trial of Lu-177 Octreotate
November 20, 2012
Excel Diagnostics and Nuclear Oncology Center in Houston, Texas, is the first center in the United States to start recruiting patients in a multicenter randomized clinical trial of Lu-177 Octreotate in patients with progressive midgut carcinoid. …
READ MOREFDA Approves Amendment for PRRT Clinical Trial in Texas
August 2, 2012
BREAKING NEWS: The Food and Drug Administration (FDA) has just approved the RadioIsotope Therapy of America (RITA) Foundation’s amendment to the Investigational New Drug (IND) protocol for intra-hepatic artery administration of Lu-177 Octreotate…
READ MORE